文献速递肾小球疾病

奥法木单抗治疗利妥昔单抗耐药或不耐受的原发性膜性肾病

Ofatumumab in Rituximab-Resistant and Rituximab-Intolerant Patients With Primary Membranous Nephropathy: A Case Series.
PubMed 文献 · Am J Kidney Dis · 2023-09-29

该病例系列纳入17例原发性膜性肾病伴肾病综合征患者,其中7例对利妥昔单抗不耐受、10例耐药,接受奥法木单抗50-300mg单次静脉输注。中位随访5.0个月,7例不耐受者及3例耐药者达到完全或部分缓解,所有患者B细胞均耗竭,抗PLA2R抗体下降,24个月时eGFR平均较基线升高13.4%(P=0.036)。

要点

  • 奥法木单抗可使利妥昔单抗不耐受的膜性肾病患者全部达到完全或部分缓解。
  • 利妥昔单抗耐药者中仅3/10达到缓解,疗效不及不耐受者。
  • 所有患者1周内B细胞耗竭,抗PLA2R抗体在部分患者中降至<2.7 RU/mL。

核心结论

  • 奥法木单抗可能对利妥昔单抗不耐受的膜性肾病有效且安全,但需更大前瞻性研究验证。

研究设计与样本

  • 病例系列,纳入2015年9月至2019年1月在意大利贝加莫肾脏科随访的17例原发性膜性肾病伴肾病综合征患者,其中7例利妥昔单抗不耐受、10例耐药,接受奥法木单抗50-300mg单次静脉输注。

主要发现

  • 中位随访5.0(IQR 3.0-9.8)个月,7例利妥昔单抗不耐受者全部及10例耐药者中3例达到完全(蛋白尿<0.3g/d)或部分(蛋白尿<3.5g/d且较基线下降≥50%)缓解。
  • 所有患者1周内循环B细胞均耗竭;抗磷脂酶A2受体抗体在4例不耐受者中3例、8例耐药者中4例降至<2.7相对单位/mL。
  • 奥法木单抗显著降低24小时尿蛋白和免疫球蛋白G排泄,升高血清白蛋白和免疫球蛋白G水平,且在不耐受者中效应大于耐药者。
  • 所有患者24个月时测得肾小球滤过率平均较基线升高13.4%(P=0.036)。
  • 9例患者发生14次非严重输注相关不良事件,经暂时中断输注后恢复。

临床怎么用

  • 奥法木单抗可能作为利妥昔单抗不耐受的原发性膜性肾病患者的替代治疗选择。

局限性

  • 回顾性设计,患者数量有限。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

RATIONALE & OBJECTIVE: Rituximab is the first-choice therapy for patients with primary membranous nephropathy (MN) and nephrotic syndrome. However, approximately 30% of patients are treatment-resistant or become treatment-intolerant with hypersensitivity reactions upon repeated drug exposures. We aimed to assess whether ofatumumab, a fully human second-generation anti-CD20 antibody, could be a valuable alternative to rituximab in this population. STUDY DESIGN: Case series. SETTING & PARTICIPANTS: 7 rituximab-intolerant and 10 rituximab-resistant patients with MN who consented to receive ofatumumab (50-300mg, single intravenous infusion) and were followed at the nephrology unit of Azienda Socio-Sanitaria Territoriale Papa Giovanni XXIII (Bergamo, Italy) between September 2015 and January 2019. FINDINGS: Over a median (IQR) follow-up of 5.0 (3.0-9.8) months, all 7 rituximab-intolerant and 3 of the 10 rituximab-resistant patients exhibited complete (proteinuria<0.3g/d) or partial (proteinuria<3.5g/d with≥50% reduction vs baseline) remission of nephrotic syndrome. Circulating B cells were similarly depleted in all patients by 1 week, and serum anti-phospholipase A2 receptor antibody concentrations decreased to<2.7 relative units/mL in 3 of 4 rituximab-intolerant and 4 of 8 rituximab-resistant patients with phospholipase A2 receptor-related disease. Ofatumumab significantly reduced 24-hour urinary protein and immunoglobulin G excretion and increased serum albumin and immunoglobulin G levels. These effects were greater in rituximab-intolerant than in rituximab-resistant patients. Measured glomerular filtration rate significantly increased by an average of 13.4% at 24 months compared with baseline (P=0.036) among all patients in the series. There were 14 nonserious infusion-related adverse events in 9 patients that recovered with temporary infusion interruption. LIMITATIONS: Retrospective design, limited number of patients. CONCLUSIONS: Ofatumumab may represent an effective and safe treatment for rituximab-intolerant cases of MN. Larger prospective studies will be needed to validate these preliminary findings and explore the effectiveness of other second-generation anti-CD20 antibodies in this clinical setting. PLAIN-LANGUAGE SUMMARY: Primary membranous nephropathy (MN) is one of the most frequent causes of nephrotic syndrome (NS) in adults. In this case series, we explored the efficacy of ofatumumab, a fully human second-generation anti-CD20 antibody, in 17 patients with MN and NS who were intolerant or unresponsive to rituximab. All 7 rituximab-intolerant patients exhibited complete or partial clinical remission, compared with only 3 of the 10 rituximab-resistant patients. Autoantibody levels decreased in all patients with phospholipase A2 receptor-related disease. Ofatumumab achieved a significant reduction in urinary protein and immunoglobulin G excretion while increasing serum albumin and immunoglobulin G levels. Ofatumumab may be a promising option for patients with MN who are rituximab-intolerant. Further investigations are warranted to validate these preliminary findings.

来源:Am J Kidney Dis,查看原文。版权归原作者所有。

引用

  1. Podestà MA, Trillini M, Portalupi V, et al. Ofatumumab in Rituximab-Resistant and Rituximab-Intolerant Patients With Primary Membranous Nephropathy: A Case Series. Am J Kidney Dis. 2023. PMID: 37777061. doi:10.1053/j.ajkd.2023.08.010

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。